Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Takeda Accelerates Access to its Dengue Vaccine Through 'Make in India' Manufacturing Partnership with Biological E. 2024-02-27 12:40
OrigiMed and Takeda Announced Partnership to Accelerate R&D and Commercialization of Innovative Medicines 2020-11-11 21:26
Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate 2019-09-06 05:59
Takeda, Microsoft and EURORDIS release report with action plan to help rare disease community shorten the diagnostic odyssey 2019-02-20 19:07
New Post-Hoc Analyses Report Early Symptomatic Improvement in Moderately to Severely Active Ulcerative Colitis or Crohn's Disease Patients Taking Entyvio® (vedolizumab), Particularly in Biologic-Naïve Patients 2017-10-16 20:16
Takeda and Marvel Custom Solutions Debut the Full IBD Unmasked Graphic Novel Featuring a Team of Inflammatory Bowel Disease (IBD) Super Heroes 2017-08-02 16:30
Takeda and Marvel Custom Solutions Launch the Latest Adventure of the IBD Unmasked Super Hero Squad in Celebration of World IBD Day 2017 2017-05-19 14:11
New Real-World Analyses Support Effectiveness and Safety of Entyvio(R) (vedolizumab) for Ulcerative Colitis and Crohn's Disease 2017-05-08 23:08
Five-Year Open-Label Prospective Study Data Presented at the 12th Congress of European Crohn's and Colitis Organisation (ECCO) Provides Information on the Long-Term Use of Vedolizumab in Adult Patients with Moderate to Severely Active Ulcerative Colitis and Crohn's Disease 2017-02-17 20:13
GEMINI II & III Post-hoc Analysis Reports Clinical Benefits of Vedolizumab 2016-12-09 23:18
Takeda Unmasks Four New Super Heroes at London's Comic Con to Highlight the Strength of those Living with Inflammatory Bowel Disease (IBD) with the Support of Marvel Custom Solutions 2016-10-28 16:05
Takeda's Vedolizumab Demonstrated Robust Clinical Effectiveness and Safety in Inflammatory Bowel Disease in More Than 50 Real-World Studies 2016-10-17 14:00
Additional Interim Data Supporting Long-Term Use of Vedolizumab in Patients with Ulcerative Colitis and Crohn's Disease Published in Journal of Crohn's and Colitis 2016-09-29 03:49
Favorable Benefit: Risk Profile for Vedolizumab as Induction and Maintenance Therapy in TNF-Naïve or TNF-Failure Patients with Moderately to Severely Active Ulcerative Colitis Published in Clinical Gastroenterology and Hepatology 2016-09-18 10:54
Takeda and TiGenix Announce Publication in The Lancet of 24-Week Results of the Phase 3 ADMIRE-CD Trial Investigating Cx601 in the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease 2016-08-02 15:19
IBD Unmasked, a First-of-its-Kind Global Awareness Initiative, Launches to Support and Empower the Inflammatory Bowel Disease Community 2016-07-13 16:55
Takeda and TiGenix Enter into Licensing Agreement for Ex-U.S. Rights to Cx601 for the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease 2016-07-05 14:14
EXAMINE Trial Post-Hoc Analyses of Mortality Data Regarding Cardiovascular Safety of Alogliptin Presented at American Diabetes Association's 76th Scientific Sessions and Published in Diabetes Care 2016-06-12 11:10
Takeda Licenses Global Rights to Theravance Biopharma's TD-8954, a Novel 5-HT4 Agonist and Motility Agent for Gastrointestinal Motility Disorders 2016-06-08 21:02
Takeda to Present New Data at the American Diabetes Association's 76th Scientific Sessions 2016-06-07 01:09
1 2